Treatment options are limited for advanced-stage ESCC.
Results conflict with trial findings of fewer pulmonary complications with MIE.
Findings in matched analysis strengthen confidence in observational results.
Meta-analysis of observational studies confirms the association.
The device could be a non-invasive diagnostic tool to screen primary care patients before referral for endoscopy.
The strategy could be especially appropriate with baseline or high risk for peripheral neuropathy.
The test shows high specificity, sensitivity, and predicted tissue of origin.
The current standard dose for local-regional control in esophageal cancer is lower than that used for other tumor sites.
A study of more than 1000 patients attending the Northern Oesophagogastric Unit in Newcastle upon Tyne.
Results from a population-based cohort study including 4,527,633 participants.
Data from 146,152 adults participating in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial.
Data on treatment strategies for BR-ESCC are limited.
Preclinical studies as well as studies in breast cancer suggest that dual HER2 therapy might improve outcomes.
Neoadjuvant chemoradiation has a survival benefit in squamous cell carcinoma, but it is unclear whether it benefits esophageal cancer patients more broadly, especially those with adenocarcinoma.
Delayed and salvage esophagectomy have been found to be associated with worse outcomes in previous studies.
Guidance from Guy’s & St Thomas’ Oesophago-Gastric Research Group
Previous studies have shown mixed results with neoadjuvant radiation.
